‘Celling Biosciences (“Celling”), based in Austin, Texas, acquired all the assets and stock of ThermiGen, the aesthetic device division of Spanish pharmaceutical leader Almirall. ThermiGen, founded in Dallas in 2012, commercializes a unique line of radiofrequency-based devices utilized by plastic surgeons, dermatologists, obstetricians/gynecologists and cosmetic physicians. Thermi has a strong base of over 2,000 users and generated $18 MM of net sales in 2018.’

Celling Biosciences, a pioneer in cellular therapy, acquires rights to ThermiGen
Source: BioSpace

Read the full article HERE